Kim Theilgaard-Mønch

Kim Theilgaard-Mønch

Clinical Associate Professor, Group leader

Member of:

    Primary fields of research

    Acute Myeloid Leukemia – Leukemic Stem Cells and Clinical Trials

    Hematopoietic stem cells


    Current research

    Identification and therapeutic targeting of "oncogenic" signaling and DNA damage response pathways in preclinical models of human AML.

    Novel antibody-drug conjugate therapy targeting leukemic stems cells in AML patients.

    Sponsoring PI of translational exploratory investigator-initiated AML trial in collaboration with 14 Nordic AML centers. Our trial conducts extensive AML profiling including genomics, transcriptomics, phosphoproteomics, and ex vivo drug screening to identify novel effective drug combinations targeting therapy-resistant minimal residual disease/leukemic stem cells in AML patients.

    Application of our novel human hematopoietic stem cell markers for (i) refinement of the human HSC phenotype and (ii) production of highly purified stem cell grafts applicable for autologous stem cell transplantation of AML and other cancer patients, as well as gene therapy of patients with monogenic diseases.

    Fields of interest

    Acute Myeloid Leukemia – therapeutic targeting of leukemic stem cells

    Translational exploratory investigator-initiated AML trials in collaboration with the Nordic AML Group

    Hematopoietic stem cells - biology and clinical application

    Normal and malignant hematopoietic/myeloid development


    ID: 3997971